OncoGenex Pharmaceuticals to Present at the 14th Annual Needham Healthcare Conference

BOTHELL, Wash. and VANCOUVER, British Columbia, April 9, 2015 /CNW/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, President and Chief Executive Officer, will provide a corporate presentation at the 14th Annual Needham Healthcare Conference on April 15, 2015 at the Westin Grand Central Hotel in New York City. The presentation will include an overview of the company's lead product candidates and anticipated clinical events.

The presentation will begin at 3 p.m. ET and a live audio webcast can be accessed via http://wsw.com/webcast/needham71/ogxi or the Investor Relations page of the OncoGenex website at www.OncoGenex.com. The webcast replay will be archived for 90 days.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development. More information is available at www.OncoGenex.com and at the company's Twitter account:  https://twitter.com/OncoGenex_IR.

SOURCE OncoGenex Pharmaceuticals, Inc.

For further information: OncoGenex Contact: Jim DeNike, jdenike@oncogenex.com, (425) 686-1514, http://oncogenex.com


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890